| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:16758764 | IVR | 67 mg/L | 67 mg/L | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| IVR | 67 mg/L | 67 mg/L | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVR | 50 mg/L | - | No significant effects observed | - | |
| IVR | 30 mg/L | - | No significant effects observed | - | |
| PMID:2092650 | IVR | 20 mg/kg | 20 mg/kg | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations |
| IVR | 20 mg/kg | 20 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects acetylcholinesterase activity | Neurological endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Increased Lactate dehydrogenase (LDH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects glycogenolysis | Metabolic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects gluconeogenesis | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Affects acetylcholinesterase activity | Neurological endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Increased Lactate dehydrogenase (LDH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Affects gluconeogenesis | Metabolic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Affects glycogenolysis | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | - | No significant effects observed | - | |
| PMID:22284168 | IVR | 8.2 mg/kg/day | 8.2 mg/kg/day | Decreased FSH levels | Reproductive endocrine-mediated perturbations |
| IVR | 8.2 mg/kg/day | 8.2 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 4.1 mg/kg/day | 4.1 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 4.1 mg/kg/day | 4.1 mg/kg/day | Increased estrogen levels | Reproductive endocrine-mediated perturbations | |
| IVR | 4.1 mg/kg/day | 4.1 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 4.1 mg/kg/day | 4.1 mg/kg/day | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 4.1 mg/kg/day | 4.1 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 4.1 mg/kg/day | 4.1 mg/kg/day | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 4.1 mg/kg/day | 4.1 mg/kg/day | Affects acetylcholinesterase activity | Neurological endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | - | No significant effects observed | - | |
| IVR | 8.2 mg/kg/day | 8.2 mg/kg/day | Affects acetylcholinesterase activity | Neurological endocrine-mediated perturbations | |
| IVR | 8.2 mg/kg/day | 8.2 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 8.2 mg/kg/day | 8.2 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 8.2 mg/kg/day | 8.2 mg/kg/day | Affects fertility | Reproductive endocrine-mediated perturbations | |
| PMID:30219569 | IVTH | 0.0005 M | 0.0005 M | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0005 M | 0.0005 M | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| PMID:599594 | IVR | 9 mg/kg/day | 9 mg/kg/day | Changes in brain morphology | Neurological endocrine-mediated perturbations |
| IVR | 0.18 mg/kg/day | 0.18 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 0.18 mg/kg/day | 0.18 mg/kg/day | Affects litter size | Reproductive endocrine-mediated perturbations | |
| PMID:8062636 | IVR | 0 NA | - | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0 NA | - | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0 NA | - | Decreased weights of accessory sex organs | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.